Terazosin Capsule
Product Images NDC 71610-780

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Terazosin (NDC 71610-780). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 10 mg (71610 0780 60)

Label for Terazosin Hydrochloride 10 mg capsules indicating a 90-capsule package. The label includes storage instructions to keep between 20-25 degrees Celsius and to protect from light, along with a warning to keep out of reach of children. The manufacturer is Jubilant Cadista Pharmaceuticals Inc. in Salisbury, MD, and the repackager is Aphena Pharma Solutions - Tennessee, LLC in Cookeville, TN. The label also features NDC 71610-0780-60 and batch/expiration details.*

FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Terazosin Hydrochloride Chemical Structure (Terazosin Hydrochloride Capsules 1)

Chemical structure of Terazosin Hydrochloride, depicting its molecular framework including fused rings and functional groups characteristic of the compound.*

FDA Label Image

Figure 1 (Terazosin Hydrochloride Capsules 2)

This figure presents two line graphs comparing placebo and Terazosin over three months. The left graph shows mean change in total symptom score from baseline, with Terazosin decreasing symptoms more than placebo. The right graph depicts mean increase in peak flow rate (mL/sec) from baseline, with Terazosin showing a greater increase than placebo over time.*

FDA Label Image

Figure 2 (Terazosin Hydrochloride Capsules 3)

A line graph showing mean change from baseline over time in months, with data points plotted from month 0 to month 30. The vertical axis represents mean change values, decreasing from 0 to approximately -7. The graph includes multiple data points with some marked by asterisks indicating statistical significance.*

FDA Label Image

Figure 3 (Terazosin Hydrochloride Capsules 4)

A line graph depicting the mean change from baseline in urinary leakage over time in months, from 0 to 30. Data points are marked with error bars and several points with asterisks indicating statistical significance.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.